A carregar...
CDK4/6 Inhibitors in Cancer Therapy: A Novel Treatement Strategy for Bladder Cancer
Patients with metastatic bladder cancer (mBC) treated with cisplatin-based chemotherapy have a limited median survival of only around 14 months [1]. Despite over 30 years of basic and clinical research, until recently no therapeutic options beyond cisplatin-based therapy had entered clinical routine...
Na minha lista:
| Publicado no: | Bladder Cancer |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
IOS Press
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5409046/ https://ncbi.nlm.nih.gov/pubmed/28516152 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3233/BLC-170105 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|